Drug intelligence / Profile preview

PRT-K4

Development stage: Discontinued
Lead developer: Prelude Therapeutics
Modality: Small Molecules

Overview

**PRT-K4** is a preclinical small-molecule protein kinase inhibitor from Prelude Therapeutics being explored for oncology. Available public information describes it as a highly selective kinase inhibitor intended for the treatment of cancer, but does not clearly disclose the exact kinase target, specific tumor type focus, route, dosage form, or formulation. The program appears to have been discontinued while still in preclinical development.

Targets

PK (Pyruvate kinase)

Beyond the preview

Go deeper on PRT-K4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRT-K4.

Explore the full profile